Larotrectinib Sulfate and Verapamil Extended Release Tablets
Determining the interaction of Larotrectinib Sulfate and Verapamil Extended Release Tablets and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Verapamil may increase the blood levels of larotrectinib in some patients. This may increase the risk and/or severity of side effects such as dizziness, confusion, coordination problems, memory problems, liver problems, and tingling, numbness or burning in the hands and feet. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. You should seek immediate medical attention if you have fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark urine, pale stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with inhibitors of CYP450 3A4, P-glycoprotein (P-gp), or breast cancer resistance protein (BCRP) may increase the plasma concentrations of larotrectinib, which is primarily metabolized by the isoenzyme. When a single 100 mg dose of larotrectinib was coadministered with itraconazole, a potent CYP450 3A4 inhibitor and P-gp and BCRP inhibitor, larotrectinib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 2.8- and 4.3-fold, respectively, compared to administration of larotrectinib alone. The interaction has not been studied with other, less potent CYP450 3A4 inhibitors.
MANAGEMENT: Caution is advised when larotrectinib is used with CYP450 3A4, P-gp, and/or BCRP inhibitors. Patients should be monitored for adverse effects such as neurotoxicity (delirium, dysarthria, dizziness, gait disturbance, paraesthesia, encephalopathy, memory impairment, tremor) and hepatotoxicity (elevations in liver transaminases), and the larotrectinib dosage adjusted as necessary in accordance with the product labeling.
- "Product Information. Vitrakvi (larotrectinib)." Bayer Pharmaceutical Inc, West Haven, CT.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Generic Name: larotrectinib
Brand name: Vitrakvi
Synonyms: Larotrectinib
Generic Name: verapamil
Brand name: Calan, Isoptin SR, Verelan, Isoptin, Calan SR, Isoptin IV, Covera-HS, Verelan PM
Synonyms: Verapamil
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Larotrectinib Sulfate-Verapamil Hydrochloride
- Larotrectinib Sulfate-Verapamil Hydrochloride PM
- Larotrectinib Sulfate-Verapamil Immediate-Release Tablets
- Larotrectinib Sulfate-Verapamil Injection
- Larotrectinib Sulfate-Verapamil Intravenous
- Larotrectinib Sulfate-Verapamil Long-Acting Capsules
- Verapamil Extended Release Tablets-Lartruvo
- Verapamil Extended Release Tablets-Larynex
- Verapamil Extended Release Tablets-Laryng-O-Jet
- Verapamil Extended Release Tablets-Laryngesic
- Verapamil Extended Release Tablets-Lasix
- Verapamil Extended Release Tablets-Lasix Injection